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Public health preparedness for coronavirus (CoV) disease 2019 (COVID-19) is challenging in the absence of setting-specific epidemi-
ological data. Here we describe the epidemiology of seasonal CoVs (sCoVs) and other cocirculating viruses in the West of Scotland, 
United Kingdom. We analyzed routine diagnostic data for >70 000 episodes of respiratory illness tested molecularly for multiple 
respiratory viruses between 2005 and 2017. Statistical associations with patient age and sex differed between CoV-229E, CoV-OC43, 
and CoV-NL63. Furthermore, the timing and magnitude of sCoV outbreaks did not occur concurrently, and coinfections were not 
reported. With respect to other cocirculating respiratory viruses, we found evidence of positive, rather than negative, interactions 
with sCoVs. These findings highlight the importance of considering cocirculating viruses in the differential diagnosis of COVID-19. 
Further work is needed to establish the occurrence/degree of cross-protective immunity conferred across sCoVs and with COVID-
19, as well as the role of viral coinfection in COVID-19 disease severity.
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In March 2020, the World Health Organization declared the 
global spread of coronavirus (CoV) disease 2019 (COVID-19), 
caused by a human CoV (severe acute respiratory syndrome CoV 
[SARS-CoV-2]) that emerged in China in December 2019, a pan-
demic [1]. Predicting the public health impact of pathogens with 
recently acquired human-to-human transmissibility is a chal-
lenge. Currently, the fate of COVID-19 remains unclear; under-
standing the likely age and seasonal profiles of infection risks will 
be critical to inform effective surveillance and control strategies.
During the early phase of an outbreak, in the absence of de-
tailed country-specific knowledge, preliminary risk estimates 
may be gauged from endemic pathogens with similar modes 
of transmission. The infection incidence and levels of severe 
illness associated with COVID-19 remains unclear. In this in-
stance, epidemiological data on seasonal CoVs (sCoVs) may 
provide valuable information about individuals and seasonal 
conditions favoured by, or limiting, an invading CoV.
To date, emergent zoonotic human CoVs associated with 
high case-fatality ratios have not achieved persistence in the 
human population. SARS-CoV emerged in 2002 and spread 
rapidly around the globe before being successfully contained 
in 2003 [2]. Conversely, Middle East respiratory syndrome 
CoV has continued to cause sporadic cases predominantly 
in healthcare settings since its discovery in 2012, but has not 
demonstrated sustained community transmission [3]. In con-
trast, CoV-229E, CoV-NL63, CoV-OC43, and CoV-HKU1 are 
common cocirculating sCoVs predominantly associated with 
mild infection of the upper respiratory tract [4].
A key determinant governing the invasion and persist-
ence success of a new pathogen is the abundance of suscep-
tible hosts. Such population susceptibility may be difficult 
to define owing to preexisting cross-protective immunity in 
individuals previously exposed to antigenically related patho-
gens, as demonstrated for pandemic influenza A  H1N1 in 
2009 [5]. Furthermore, the potential for heterologous inter-
actions among taxonomically broad groups of respiratory 
viruses is also recognized [6–11]. A  good epidemiological 
understanding of cocirculating viruses will provide valuable 
information on the potential for immune, or otherwise medi-
ated, virus-virus interactions and the consequences for pop-
ulation susceptibility.
To date, epidemiological knowledge surrounding sCoVs has 
been limited for many settings owing to their historic associa-
tion with mild illness. However, some laboratories have adopted 
sCoV testing as part of routine multiplex diagnostic screens 
[12–15], following an increased recognition of the associated 
disease spectrum. Our group previously reported on the com-
parative epidemiological characteristics of acute viral respira-
tory infections, and the potential for virus-virus interactions, 
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based on multiplex reverse-transcription polymerase chain re-
action (PCR) testing in the West of Scotland [6, 16]. In the cur-
rent article, we provide further detail on sCoVs differentiated at 
the species level (sCoV types) over an extended time frame and 
discuss key potential implications for COVID-19 virus emer-
gence in Scotland, United Kingdom.
METHODS
The Study Population
Routine molecular testing for CoV-229E, CoV-OC43, and 
CoV-NL63 using multiplex real-time reverse-transcription 
PCR methods was conducted between 1 January 2005 and 30 
September 2017 by the West of Scotland Specialist Virology 
Centre in NHS Greater Glasgow and Clyde, the largest Scottish 
National Health Service (NHS) board serving a population of 
approximately 1.2 million [17]. The respiratory virus screen 
also simultaneously detected influenza A  virus, influenza B 
virus, respiratory syncytial virus (RSV), human adenoviruses 
(AdVs), human rhinoviruses, human metapneumovirus, and 
parainfluenza virus (PIV) types 1–4. The CoV-HKU1 assay was 
discontinued in 2012 owing to low levels of detection. Most clin-
ical specimens (91%) were obtained from the upper respiratory 
tract (the majority being nasal and/or throat swab samples).
During the study period, 107  174 clinical respiratory sam-
ples, from 64 948 individual patients, were received by the West 
of Scotland Specialist Virology Centre for testing. For patients 
with ≥2 samples submitted (24.5% of patients), the PCR test 
data were aggregated into individual episodes, defined as a 
30-day period from the collection date of the first sample. This 
generated 84  957 episodes of respiratory illness for analysis. 
Most episodes, 93% that occurred out with the 3 major waves 
of pandemic influenza A(H1N1)pdm09 virus circulation in 
the United Kingdom (summer 2009 and influenza seasons of 
2009–2010 and 2010–2011), were tested for all 11 groups of res-
piratory virus. Of 84 957 episodes of respiratory illness, 10 438 
were not tested for CoV (98% during the 3 major waves of pan-
demic influenza) and thus were excluded from analyses cen-
tered on sCoVs [18]. Among the remaining 74 519 episodes of 
illness, another 278 were either tested for CoV-HKU1 or the 
CoV was untyped; these episodes were excluded from analyses 
differentiating sCoV type. See Figure 1 for a summary of the 
data subsets.
Statistical Modeling Analyses
Of 74  241 patient episodes of respiratory illness with sCoV 
subtyping, 8912 patients experienced multiple episodes over 
the study time frame. In such cases, we retained the first ob-
served episode to remove patient-level clustering, leaving 
56  276 patient observations for analysis (Figure  1). We used 
multivariable logistic regression to investigate associations be-
tween sCoV types (CoV-229E, CoV-OC43, and CoV-NL63) 
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Figure 1. Data flow diagram summarizing patient subsets informing each analysis. Samples from 64 948 patients were subjected to molecular tested for respiratory vir-
uses, performed with real-time multiplex reverse-transcription polymerase chain reaction in NHS Greater Glasgow and Clyde, Scotland, United Kingdom, between 1 January 
2005 and 30 September 2017. Abbreviation: sCoV, seasonal coronavirus.
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and patient age (categorical), sex (binary), healthcare service 
setting (binary; primary or secondary or tertiary services), time 
period with respect to the 3 major waves of pandemic influenza 
in the United Kingdom (categorical; prepandemic, January 
2005 to April 2009; pandemic, May 2009 to February 2011; and 
postpandemic, March 2011 to September 2017)  and season 
(categorical). Statistical interactions between patient covariates 
and healthcare service setting were assessed. An α level of 5% 
was used to determine statistical significance of all model coef-
ficients. The fitted models, incorporating age-healthcare service 
interactions, were used to generate average predicted probabil-
ities of virus detection by age and healthcare setting.
In addition, we used multivariable logistic regression to in-
vestigate interactions between each sCoV and other groups of 
respiratory viruses at the within-host scale. These analyses were 
based on 16 991 virus-positive episodes of respiratory illness, 
retaining the first observed episode of illness for patients with 
multiple episodes. Virus-negative patients were excluded to 
eliminate the influence of Berkson bias, which may lead to spu-
rious inference of disease-disease associations when these are 
estimated from routine healthcare data [19]. Specifically, these 
analyses tested whether the odds of a given virus (“exposed”) 
coinfecting with a given sCoV differed from the average odds 
among the remaining groups of viruses (“nonexposed”), thereby 
assessing nonrandom mixing among the virus population.
Three models were fitted, one each for CoV-229E, CoV-OC43, 
and CoV-NL63 (response variables). The analyses adjusted for 
patient age, sex, healthcare service setting, time period with 
respect to pandemic influenza (as described above), and the 
monthly background prevalence of the sCoV (response var-
iable) to eliminate spurious virus-virus associations owing to 
unrelated sources of seasonality. Holm’s method was used to 
correct P values for multiple comparisons (10 virus-virus inter-
action hypotheses per model) [20].
All analyses were conducted using R software version 3.4.4 
[21]. Logistic regression modeling was conducted using the 
“glm” function, and predicted probabilities were computed 
using “ggaverage” from the “ggeffects” package [22].
RESULTS
Prevalence of sCoVs Among People With Respiratory Illness
Among 84 957 episodes of respiratory illness, 79.0% were sam-
pled at secondary or tertiary healthcare services (hospital in-
patients and outpatients), and 21.0% from primary healthcare 
services (general practice [GP]). The sex distribution was ap-
proximately equal, with 51.6% of patients female, and the me-
dian age was 33.1 years (interquartile range, 5.6–59.1 years).
The prevalence of sCoV detections overall was 4.0% among 
tested patients (2958 of 74 519), contributing to 10.7% (2958 of 
27 734) of all respiratory virus detections. Figure 2 summarizes 
the contribution of sCoVs to the total viral detections in the pa-
tient population during each influenza season (October–May) 
from 2005 to 2016. The most common virus detections during 
influenza seasons among virus-positive patients were human 
rhinoviruses (range, 15.3%–46.2%), influenza viruses (13.4%–
34.0%, excluding pandemic influenza waves of 2009–2010 
and 2010–2011), and RSV (10.1%–21.9%), followed by sCoVs 
(7.7%–7.4%) (Figure 2).
Numbers of sCoV detections increased before pandemic in-
fluenza (March 2011 to September 2017), likely owing to en-
hanced virological testing of acute respiratory illnesses; the 
overall number of sCoV detections rose from 545 before, to 2072 
following the pandemic influenza period. However, a decrease 
in prevalence among the tested population was observed, from 
4.27% to 3.70%, and with varying patterns at the individual sCoV 
level (Supplementary Table 1). The most prevalent detection was 
CoV-OC43, both before and following the pandemic influenza 
period (Supplementary Table 1). CoV-HKU1 was present at a 
very low prevalence of 0.3% overall (124 of 36 652 episodes tested 
until the assay was discontinued in 2012) and was therefore ex-
cluded from further analyses.
Difference Between Patients in Detection of sCoVs
Despite more sCoV detections in the hospital setting, the 
prevalence was greatest among the tested GP attendees (5.3%; 
673 of 12  670) than among those in hospitals (3.7%; 2285 of 
61  849). Figure  3 summarizes the age distributions. Cases 
of sCoV in children <5  years old and the elderly  (>64 years) 
were disproportionately represented among patients admitted 
to the hospital, compared with a more uniform distribu-
tion among GP attendees, closely following the overall tested 
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Figure 2. Percentages of viral respiratory infections attributed to human cor-
onaviruses and other common respiratory viruses during each influenza season 
(October–May) from 2005–2006 until 2016–2017, based on 84  957 episodes of 
respiratory illness. Influenza includes influenza A  and influenza B viruses com-
bined; and “other” includes human adenoviruses, human metapneumovirus, and 
parainfluenza viruses type 1–4. Note: Years of major pandemic influenza A H1N1 
virus circulation (2009–2010 and 2010–2011) must be viewed with caution, owing 
to high levels of partial testing. Testing for CoV-HKU1was discontinued in 2012. 
Abbreviations: CoV,  human coronaviruses (CoV-229E, CoV-OC43, CoV-NL63, and 
CoV-HKU1 combined); RSV, respiratory syncytial virus; RV, human rhinovirus.
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population (Figure 3A). Different sex biases was found among 
adults depending on the healthcare setting, with more female 
patients in primary care versus more male patients in sec-
ondary or tertiary care (Figure 3B). This pattern was consistent 
when comparing the percentages of detections among sCoV-
positive patients across sCoV types: 59.2% (CoV-229E), 55.6% 
(CoV-OC43), and 59.8% (CoV-NL63) of cases detected in pri-
mary care were in female patients, whereas 54.7% (CoV-229E), 
51.1% (CoV-OC43), and 56.7% (CoV-NL63) cases detected in 
secondary or tertiary care were in male patients (Supplementary 
Table 2).
The median patient age (interquartile range) varied from 
20.9 (2.7–50.2) years for CoV-NL63, to 39.9 (5.0–62.5) and 
43.3 (16.5–60.4) years for CoV-OC43 and CoV-229E, respec-
tively. The age-specific prevalences of sCoVs among the tested 
population are summarized in Supplementary Tables 3 and 4. 
More variation across ages was found in primary care patients 
for CoV-229E (coefficient of variation, 40.4%) and CoV-NL63 
(33.8%) than for CoV-OC43 (13.6%), with less variation for pa-
tients in secondary or tertiary care (CV, 29.96% for CoV-229E, 
28.0% for CoV-NL63, and 17.10% for CoV-OC43).
Statistical modeling analyses further confirmed differences in 
age and sex associations according to sCoV type, and a greater 
chance of sCoV detection among GP attendees than among pa-
tients admitted to the hospital (Supplementary Tables 5–7). No 
evidence of significant effect modification between patient age 
or sex and healthcare service setting was found (statistical in-
teraction terms, P > .05; results not shown). Figure 4 summar-
izes average age-specific predicted probabilities with statistical 
interactions incorporated. In summary, we observed a trend to-
ward increasing probability of CoV-229E with age (Figure 4A), 
greater probabilities of CoV-OC43 at the extremities of age 
(Figure 4B), and decreasing probability of CoV-NL63 with age 
(Figure 4C). These age patterns were broadly consistent across 
patient sex and healthcare settings, although we note that 95% 
confidence intervals overlapped across all ages except for pa-
tients in the hospital setting. A borderline significant sex effect 
was found for CoV-229E, with detections more likely among 
male patients (Supplementary Table 5).
Variations in Seasonality Among sCoVs
Figure  5 shows the monthly prevalences of sCoVs detected 
among the patient population. These are winter pathogens in 
the United Kingdom, peaking on average between January and 
March. However, there were notable variations between sCoV 
types and between years. Overall, CoV-OC43 was the most 
prevalent detection among the tested population in each influ-
enza season. Differences were also observed in periodicities; 
before the first wave of pandemic influenza in 2009, CoV-
229E peaked biennially, but it subsequently exhibited longer 
interpeak periods, particularly between 2013 and 2016.
In contrast, CoV-OC43 and CoV-NL63 generally exhibited 
annual periodicity of varying magnitude. A considerable degree 
of synchrony is observed in the timing of the peak prevalence 
of CoV-OC43 and CoV-NL63 for most seasons, whereas CoV-
229E was more distinctive in its temporal pattern. For example, 
low levels of CoV-229E in 2007 coincided with high magni-
tudes of CoV-OC43 and CoV-NL63, whereas the high preva-
lence of CoV-229E in 2010 coincided with low magnitudes of 
CoV-OC43 and CoV-NL63.
Interactions Between sCoVs and Other Respiratory Viruses
The cocirculation of sCoVs with other common respiratory 
virus  raises the potential for ecological interactions, altering 
infection risks and the dynamics of population transmission. 
Our data did not permit analysis of potential within-host inter-
actions among different sCoVs because of an absence of sCoV 
coinfections, but we did evaluate the potential for within-host 
interactions between sCoVs and other common respiratory 
viruses.
To do so, we analyzed the nonrandom mixing of respiratory 
viruses among virus-positive patients using multivariable lo-
gistic regression. We found a greater propensity for CoV-OC43 
to coinfect with RSV (odds ratio,  1.68; 95% confidence in-
terval,  1.05–2.63; uncorrected P  =  .03), AdV (2.93; 1.87–4.5, 
uncorrected P < .001), and PIV3 (2.38; 1.28–4.17; uncorrected 
P = .004) (Supplementary Table 8). The associations with AdV 
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Figure 3. Age distributions of general practice (GP; primary care) and hospital 
(secondary/tertiary care) patients tested and positive for human coronavirus (CoV), 
(A) and percentages of female patients (B). Note the different y-axis scale for CoV 
cases in A. Hospital patients include inpatients and outpatients.
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and PIV3 were supported after correction of P values for mul-
tiple comparisons (P < .001 and P = .04 respectively).
No evidence of interactions with other respiratory viruses was 
found for either CoV-229E or CoV-NL63. Assessment of PIV types 
was limited by small numbers of coinfections; these viruses were 
aggregated at the genus level for the CoV-229E analysis, and PIV2 
was excluded from the CoV-NL63 analysis. See Supplementary 
Tables 9 and 10 for details and Supplementary Figure 1 for a sum-
mary. The finding for PIVB  (parainfluenza virus types 2 and 4 
combined; the human rubulavirus genus) must be treated with 
caution, because the 95% confidence interval overlaps 1. The av-
erage age-specific predicted probabilities of sCoV coinfection for 
individuals with or without coinfection with each specific respira-
tory virus are given in Supplementary Table 11.
DISCUSSION
The likely long-term impact of the recently emerged COVID-19 is 
a topic currently shrouded in uncertainty for countries worldwide. 
At the time of writing, global cases are mounting, with evidence 
of community transmission for a growing number of countries. 
In the absence of setting-specific data, an epidemiological under-
standing of related and unrelated cocirculating pathogens is prudent 
to guide preliminary estimates of who is at risk and when, and to 
develop research priorities pertaining to population susceptibility. 
Epidemiological knowledge of sCoVs is lacking for many settings 
owing to an absence of inclusion in routine diagnostic testing. Here, 
we described several key epidemiological features of sCoVs based on 
a unique data set derived from multiplex PCR diagnostic testing of a 
large, well-defined population, over a 13-year period.
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It is well known that sCoVs cocirculate endemically with 
other common respiratory viruses, and coinfections are fre-
quently observed [11, 12, 16]. In the West of Scotland, sCoVs 
typically peak in winter months alongside influenza viruses 
and RSV, as described elsewhere [12]. The common occurrence 
of sCoVs during periods of high influenza activity highlights 
the importance of considering these viruses in the differential 
diagnosis of viral respiratory infections. This is particularly per-
tinent in the context of COVID-19 emergence; cocirculating 
viruses are associated with a broad spectrum of clinical presen-
tation overlapping that of COVID-19, raising the potential for a 
large number of undiagnosed or misclassified cases in settings 
lacking the capacity for multiplexed testing. Currently in NHS 
Greater Glasgow and Clyde, Scotland, most COVID-19 testing 
is being conducted in the hospital setting, where severe cases 
of respiratory illness and high risk groups are simultaneously 
tested with a multiplex panel.
Sex-specific numbers of sCoV differed by healthcare set-
ting; we observed a trend toward female patients with sCoV for 
primary care, but male patients for secondary or tertiary care. 
This finding may reflect sex differences in healthcare-seeking 
behaviors and/or illness severity. In terms of sex differences 
in detection odds (a proxy for infection and/or severity risk), 
a statistically significant sex effect was found for CoV-229E, 
with a greater odds among male than among female patients. 
This finding is consistent with previous reports of a male bias 
for CoV-OC43 and CoV-NL63 in the hospital setting [12], and 
in relation to influenza hospitalizations and mortality rates for 
acute respiratory infections more generally [23, 24]. It has been 
proposed that differences in sex hormones may explain vari-
ation in respiratory infection susceptibility, with testosterone 
exerting an immunosuppressive effect in male and estrogen 
playing a protective role in female [25, 26]. We note, however, 
that our analyses did not control for the potential confounding 
or effect modifying role of comorbid conditions, such as chronic 
obstructive pulmonary disease and asthma, or lifestyle factors, 
such as smoking.
A greater number of sCoV cases were observed in children 
<5 years of age and in elderly persons, particularly among pa-
tients admitted to hospital. This pattern is consistent with 
overall testing trends and may therefore reflect the healthcare-
seeking behavior of concerned parents, clinician testing prac-
tices, and/or the burden of other respiratory agents, rather than 
a greater risk of infection. However, it should be borne in mind 
that these analyses were based on a patient population; the true 
community burden of mild and/or asymptomatic infections is 
likely to be much higher [27]. When aggregated into epidemi-
ological groupings, age-specific probabilities of virus detection 
varied across sCoV types.
In contrast to what is generally observed  for sCoVs, rel-
atively few COVID-19 cases have been reported thus far in 
children [28]. In the context of our study population, COVID-
19 is closely related to CoV-OC43 (both betacoronaviruses), the 
most prevalent sCoV detected among patients <5 years old. It 
is possible that preexisting cross-immunity confers protection 
and/or attenuates the severity of COVID-19, leading to fewer 
tested and hospitalized children. The comparatively lower pro-
portion positive and detection odds for school-aged compared 
with younger children may potentially reflect a sustained level 
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Figure 5. Monthly prevalence of seasonal coronaviruses (sCoVs) detected among 
patients with respiratory illness virologically tested in NHS Greater Glasgow and 
Clyde, Scotland, United Kingdom, between January 2005 and September 2017. A, 
CoV-229E. B, CoV-OC43. C, CoV-NL63. D, Comparing all sCoV types.
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of CoV-OC43 immune-mediated protection, whereas waned 
immunity is expected to leave adults more vulnerable to CoV 
infection [28]. Assuming some degree of cross-immunity with 
sCoVs, our data are consistent with fewer expected cases of 
COVID-19 in children but more among the adult population 
[29, 30]. In addition, immunosenescence may exacerbate low 
levels of protective immunity in elderly persons [30, 31].
Three key features of our data seemingly support the propo-
sition of cross-immunity. First, the contrasting age patterns of 
detection probabilities between closely related CoV-229E and 
CoV-NL63 (both alphacoronaviruses) may reflect niche segre-
gation. Second, closely related CoV-229E and CoV-NL63 also 
displayed asynchronous seasonality, in contrast to CoV-OC43 
and CoV-NL63, supporting a competition dynamic. Although 
our data did not permit in-depth analysis of CoV-HKU1, others 
have reported differences in the timing of peak detections with 
CoV-OC43 (both betacoronaviruses) [12]. Third, coinfections 
among sCoVs were not recorded in this study population, al-
though detected by others albeit at a very low frequency [12]. 
More work is needed to establish whether low coinfection fre-
quency among sCoVs supports an immune-mediated competi-
tion for hosts, or whether this reflects a limitation of diagnostic 
data that capture only a snapshot of an individual’s infection.
To our knowledge, evidence of immunological cross-
protection between human CoVs is lacking, and reports of 
antigenic cross-reactivity are inconsistent. The potential for se-
rological cross-reactivity between SARS-CoV and sCoVs has 
been shown by some [31, 32] but not others [33]. Moreover, 
although confinement of cross-reactivity at the CoV genus 
level is possible, consistent with the greater genetic related-
ness of these viruses [34, 35], more general cross-reactivity 
between CoV-OC43 and CoV-229E has also been found [36]. 
Population serological surveys will be critical for establishing 
the true burden and age distribution of sCoV infections in the 
community and the potential for cross-protective immunity.
It should be borne in mind that the implications of popu-
lation levels of cross-immunity are likely to vary according to 
the local epidemiological context. We note the predominance 
of CoV-OC43 detections previously observed in a compar-
atively urban but different Scottish patient population [14], 
a pattern more generally consistent at the Scottish national 
level [28]. Other trends observed within our study popula-
tion are consistent with the Scottish national level, such as 
peak levels of CoV-229E detection in 2010 coinciding with low 
levels of CoV-NL63 and CoV-OC43 [28]. A predominance of 
CoV-OC43 has also been observed in Sweden [16], suggesting 
a potential consistency in sCoV dominance over wider geo-
graphic areas. However, differences are also apparent, for ex-
ample, the relatively common detection of CoV-HKU1 in a 
different Scottish population [14], as also suggested in a recent 
report on respiratory virus detections in France [29].
Our study also highlights the potential for interactions be-
tween sCoVs and other respiratory viruses. In previous ex-
tensive analyses of virus-virus interactions, our group found a 
strong signal of positive interactions at the within-host scale be-
tween human CoVs overall and RSV, AdV, and PIVs (combining 
types 1 and 3; human Respirovirus genus) [6]. In the current 
study, our more in-depth analysis corroborates positive inter-
actions at the sCoV type level. For CoV-OC43, the most prev-
alent in this study population, our results support our group’s 
earlier findings of a higher propensity of coinfection with RSV, 
AdV, or PIV3 than with other respiratory viruses. Note that 
these analyses were based on routine diagnostic testing, so the 
directionality of effects could not be determined. The associa-
tion with RSV was not supported after a correction for multiple 
comparisons, although previous studies also showed a high 
proportion of sCoV coinfections with RSV [12, 37]. The role 
of viral coinfections in the severity of acute respiratory illness 
remains controversial [29–33]. Further work is needed to estab-
lish the role of viral coinfections in COVID-19 severity.
In conclusion, the public health impact of COVID-19 is likely 
to vary according to the epidemiological context and health-
care infrastructure of the population. Our findings suggest that 
continued monitoring of cocirculating respiratory viruses will 
be important for guiding accurate case ascertainment and re-
search priorities surrounding population susceptibility, and for 
assessing the comparative population and healthcare burden of 
COVID-19 in the context of multiple cocirculating respiratory 
pathogens. Further work is needed to identify the mechanism 
of interactions between human CoVs and other respiratory 
viruses, and the role of viral coinfections in the severity and 
burden of COVID-19.
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